Found 92 Vision Loss trials
A listing of Vision Loss medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
A Single-blind, Phase 2, Multi-center, Randomized Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of the Relaxin Agonist R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients with Hepatorenal Syndrome-Acute Kidney Injury
This Phase 3, double-blind, randomized, placebo-controlled, parallel-group, multi-center, international study will assess the efficacy, safety and tolerability of nebulized PC945 when added to systemic antifungal therapy for the treatment of refractory invasive pulmonary aspergillosis (IPA).
The objectives of the study are to assess the safety and efficacy of elezanumab in subjects with acute traumatic cervical SCI. The primary endpoint is the Upper Extremity Motor Score (UEMS), a subscore of the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI, 2019 criteria) during the treatment …
Patients with post-traumatic stress disorder (PTSD) will be invited to participate in this research study. Participants will be assigned to take one of the following: brexpiprazole, sertraline (also known as “Zoloft”; a marketed antidepressant that has been approved by the United States FDA for the treatment of PTSD), placebo (a …
A5394 is a phase II, randomized, double-blind, placebo-controlled clinical trial to assess the safety, tolerability, and efficacy of 24 weeks of treatment with Selgantolimod (SLGN). Intensive PK sampling will be conducted in the first 12 participants who enroll into the study.
This phase II trial investigates how well adding hydroxychloroquine to the standard treatment of dabrafenib and trametinib works to overcome resistance and delay disease progression in treating patients with stage IIIC or IV BRAF V600E/K melanoma. Giving hydroxychloroquine together with dabrafenib and trametinib may work better than dabrafenib and trametinib …
This protocol is an 18-month, multicenter, randomized, double-blind, placebo-controlled, phase 2 study comparing 1400 mg of donanemab versus placebo over 76 weeks in approximately 500 patients with early symptomatic AD. Study duration including screening and post treatment is up to 133 weeks. Study drug will be prepared and stored at …
This is a 52 wk, randomized, double-blind study to demonstarte the clinical efficacy, safety, and tolerability of ianalumab compared to placebo in patients with active Sjogren's syndrome. Pts will receive a subcutaneous injection of ianalumab/placebo monthly, in addition to salivary flow assessments, blood and urine sampling, PROs, and optional assessments …
Please see Section 1 of the attached protocol.
PROOF-HD is a placebo-controlled (double blind) multicenter Phase 3 trial of Pridopidine in Huntington Disease patients. Recruitment: 480 participants at 60 sites, a target of 8 participants per site. Procedures include administration of study drug or placebo in tablet form twice daily for a period of 67-80 weeks with option …
